Celltex News
ChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells. Celltex is continuing to monitor and participate in this effective research.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to info@celltexbank.com. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
Exploring Regenerative Medicine Beyond Stem Cell Therapy
For many, stem cell therapy is to regenerative medicine what Google is to internet searches. Yet, there are other procedures within the regenerative medicine field that may be recommended depending on the health concern being addressed.
In this article, we explore several regenerative medicine options, including platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF), and exosomes.
Read MoreWhat Makes MSCs So Promising? A Deep Dive on Mesenchymal Stem Cells
Present in the body throughout one’s lifespan, adult Mesenchymal Stem Cells (MSCs) can be used in many types of regenerative medicine. This article explores how MSCs work in the body and what makes them suitable for therapeutic application.
Read More